Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.
The company's pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.
The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification.
Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.59 Decreased by -18.00% | -0.55 Decreased by -7.27% |
| Feb 27, 24 | -0.55 Decreased by -12.24% | -0.55 |
| Nov 2, 23 | -0.50 Increased by +5.66% | -0.55 Increased by +9.09% |
| Aug 3, 23 | -0.53 Decreased by -1.92% | -0.55 Increased by +3.64% |
| May 10, 23 | -0.50 Decreased by -2.04% | -0.54 Increased by +7.41% |
| Feb 23, 23 | -0.49 Increased by 0.00% | -0.57 Increased by +14.04% |
| Nov 3, 22 | -0.53 Decreased by -6.00% | -0.56 Increased by +5.36% |
| Aug 3, 22 | -0.52 Decreased by -1.96% | -0.52 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -38.60 M Decreased by -5.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -37.17 M Decreased by -5.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -31.00 M Increased by +5.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -33.34 M Decreased by -1.83% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -36.59 M Decreased by -9.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -35.33 M Decreased by -4.96% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -32.78 M Decreased by -6.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -32.74 M Decreased by -25.17% | Decreased by N/A% Decreased by N/A% |